MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6
14 October 2024 - 11:00PM
MDxHealth to Present Third Quarter 2024
Financial Resultsand Corporate Update on November
6
Company to Host Conference Call with Live
Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET
IRVINE, CA, and HERSTAL,
BELGIUM – October 14, 2024 (GlobeNewswire) – MDxHealth SA
(NASDAQ: MDXH), a commercial-stage precision diagnostics company,
today announced it will release its financial results for the third
quarter ended September 30, 2024, after market close on Wednesday,
November 6, 2024.
|
Title: |
MDxHealth Presents Third Quarter 2024 Financial Results and
Corporate Update Conference Call and Webcast |
|
Speakers: |
Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief
Financial Officer |
|
Date: |
November 6, 2024 |
|
Time: |
4:30pm ET/ 22:30 CET |
|
Conference Call Dial-in
Details: |
United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands:
0800 94 94 506United Kingdom: 0808 238 9064 |
|
Conference ID: |
10193602 |
|
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1692944&tp_key=8f9b7ff5cf |
The webcast should be accessed 15 minutes prior to the
conference call start time. A replay of the webcast will be
available following the conclusion of the live call and will be
accessible on the Company’s website.
About MDxHealth
Mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. The Company’s U.S. headquarters and laboratory operations
are in Irvine, California, with additional laboratory operations in
Plano, Texas. European headquarters are in Herstal, Belgium, with
laboratory operations in Nijmegen, The Netherlands. For more
information, visit mdxhealth.com and follow us on social media at:
twitter.com/mdxhealth, facebook.com/mdxhealth and
linkedin.com/company/mdxhealth.
|
MDxHealth info@mdxhealth.com |
|
| LifeSci
Advisors (IR & PR)US: +1 949 271
9223ir@mdxhealth.com |
|
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate
Score, GPS and Monitor mdx are trademarks or registered trademarks
of MDxHealth SA. The GPS test was formerly known as and is
frequently referenced in guidelines, coverage policies,
reimbursement decisions, manuscripts and other literature as
Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate
Score, and Oncotype Dx Prostate Cancer Assay, among others. The
Oncotype DX trademark, and all other trademarks and service marks,
are the property of their respective owners.
MDxHealth (NASDAQ:MDXH)
Historical Stock Chart
From Oct 2024 to Nov 2024
MDxHealth (NASDAQ:MDXH)
Historical Stock Chart
From Nov 2023 to Nov 2024
